01 January 2010
Toxic tacrolimus blood levels with rifampin administration in a renal transplant recipient
Mehat Abdel Halim, Torki Al-Otaibi, Osama Gheith, Osama El-Kholy, Khaled Abdel Tawab, Tarek Said, Prasad Nair, M.R.N. NampooryAnn Transplant 2010; 15(1): 57-60 :: ID: 880570
Abstract
Background: Induction of the hepatic and intestinal cytochrome P450-3A4 system and intestinal P-glycoprotein is an unavoidable consequence of rifampin administration which requires substantial increase in tacrolimus dose when given concurrently. Chronic diarrhea is known to precipitate tacrolimus toxicity irrespective of its cause in renal transplant recipients.
Case Report: A 28 years old lady had a second renal transplant when she was 15 years old which is functioning normally. She was maintained on prednisolone, azathioprine, omeprazole and tacrolimus. Tacrolimus was maintained on therapeutic levels (5-7 ng/ml). She developed pyrexia of unknown origin associated with chronic diarrhea. Detailed investigations didn't reach any definite diagnosis. Antituberculous drugs including rifampin were started emperically. During the first four months of antituberculous treatment diarrhea worsened and unexpected high tacrolimus trough blood levels were observed requiring successive dose reduction from 7 mg/day up to 0.5mg every other day with rise of serum creatinine from 100 to 140 umol/l. Tacrolimus was changed to low dose sirolimus and renal function gradually improved to its baseline while still on rifampin treatment.
Conclusions: We conclude that chronic diarrhea may cause toxic tacrolimus blood levels even in presence of rifampin, this would be due to its significant cytochrome P450-3A4 and P-glycoprotein enzyme inhibitory effect.
Keywords: antibiotic rifampicin, Tacrolimus - pharmacokinetics, graft function, Enzyme Induction - drug effects
In Press
Case report
Tongue Carcinoma in Immunosuppressed Patients After Liver and Kidney Transplantation: A Case SeriesAnn Transplant In Press; DOI: 10.12659/AOT.951715
Original article
Prevalence and Risk Factors of Hepatic Steatosis in Kidney Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.952251
Original article
The Anatomical Landscape of Living Donor Livers: A 101-Case Retrospective Single-Center Study in Indonesia ...Ann Transplant In Press; DOI: 10.12659/AOT.952031
Original article
Decreased Ventilation Duration and ICU Stay Associated With Early Percutaneous Dilatational Tracheostomy Af...Ann Transplant In Press; DOI: 10.12659/AOT.953143
Most Viewed Current Articles
24 Aug 2021 : Review article 20,545
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 16,641
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
05 Apr 2022 : Original article 15,898
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 15,796
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988






